Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7973107rdf:typepubmed:Citationlld:pubmed
pubmed-article:7973107lifeskim:mentionsumls-concept:C0681867lld:lifeskim
pubmed-article:7973107lifeskim:mentionsumls-concept:C0001927lld:lifeskim
pubmed-article:7973107lifeskim:mentionsumls-concept:C0232187lld:lifeskim
pubmed-article:7973107lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:7973107lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:7973107lifeskim:mentionsumls-concept:C1527303lld:lifeskim
pubmed-article:7973107pubmed:issue4lld:pubmed
pubmed-article:7973107pubmed:dateCreated1994-12-8lld:pubmed
pubmed-article:7973107pubmed:abstractTextDespite concern over possible adverse cardiac effects of high-dose beta-agonists there have been no controlled studies of the effects of such a therapy in patients with severe chronic airflow obstruction (CAO). We therefore studied 22 CAO patients (FEV < 1 litre) with continuous ambulatory cardiac monitoring. Patients received either nebulised salbutamol (5 mg) or saline each given 4 times daily for 24 h on 2 consecutive days, single blind, in random order. Supraventricular arrhythmias were common on both saline and salbutamol days (8 vs. 9 patients, p = NS), but none were clinically apparent. There were no episodes of ventricular tachycardia. Ventricular ectopic activity was highly variable but did not significantly differ between the two study days overall or between specific periods after nebulised salbutamol or saline. Serum potassium (mean) fell by 0.23 (SD 0.06) mmol/l in 10 patients after salbutamol. Baseline FEV1, PaO2, PCO2 were not predictive of arrhythmias or ectopic activity. While occasional adverse effects cannot be excluded, we conclude that high-dose salbutamol does not lead to any general increase in arrhythmogenic potential in severe CAO.lld:pubmed
pubmed-article:7973107pubmed:languageenglld:pubmed
pubmed-article:7973107pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7973107pubmed:citationSubsetIMlld:pubmed
pubmed-article:7973107pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7973107pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7973107pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7973107pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7973107pubmed:statusMEDLINElld:pubmed
pubmed-article:7973107pubmed:issn0025-7931lld:pubmed
pubmed-article:7973107pubmed:authorpubmed-author:JohnstonI DIDlld:pubmed
pubmed-article:7973107pubmed:authorpubmed-author:HallI PIPlld:pubmed
pubmed-article:7973107pubmed:authorpubmed-author:WoodheadM AMAlld:pubmed
pubmed-article:7973107pubmed:issnTypePrintlld:pubmed
pubmed-article:7973107pubmed:volume61lld:pubmed
pubmed-article:7973107pubmed:ownerNLMlld:pubmed
pubmed-article:7973107pubmed:authorsCompleteYlld:pubmed
pubmed-article:7973107pubmed:pagination214-8lld:pubmed
pubmed-article:7973107pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:meshHeadingpubmed-meshheading:7973107-...lld:pubmed
pubmed-article:7973107pubmed:year1994lld:pubmed
pubmed-article:7973107pubmed:articleTitleEffect of high-dose salbutamol on cardiac rhythm in severe chronic airflow obstruction: a controlled study.lld:pubmed
pubmed-article:7973107pubmed:affiliationDepartment of Respiratory Medicine, University Hospital, Queen's Medical Centre, Nottingham, UK.lld:pubmed
pubmed-article:7973107pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7973107pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7973107pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7973107pubmed:publicationTypeRandomized Controlled Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7973107lld:pubmed